What we do?
Keith has a strong track record from numerous IP diligences for mergers and acquisitions, from small transactions to transactions valued at over $1B for S&P 500 companies since the early 2000s. In his role at Edwards Lifesciences, he was one of the few executives on the strategic alliance committee and provided strategic IP guidance for medical device start-ups that received investments or purchase option deals, with an eye toward strategic exits. Keith’s practice has the flexibility of offering hourly rates or alternative equity arrangements that can be attractive to start-ups, lenders, or investors.